RT Journal Article SR Electronic T1 A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19013078 DO 10.1101/19013078 A1 Parul Verma A1 Jayachandran Devaraj A1 Jodi L. Skiles A1 Tammy Sajdyk A1 Richard H. Ho A1 Raymond Hutchinson A1 Elizabeth Wells A1 Lang Li A1 Jamie Renbarger A1 Bruce Cooper A1 Doraiswami Ramkrishna YR 2020 UL http://medrxiv.org/content/early/2020/04/14/19013078.abstract AB Vincristine is a core chemotherapeutic drug administered to pediatric acute lymphoblastic leukemia patients. Despite its efficacy in treating leukemia, it can lead to severe peripheral neuropathy in a sub-group of the patients. Peripheral neuropathy is a debilitating and painful side-effect that can severely impact an individual’s quality of life. Currently, there are no established predictors of peripheral neuropathy incidence during the early stage of chemotherapeutic treatment. As a result, patients who are not susceptible to peripheral neuropathy may receive sub-therapeutic treatment due to an empirical upper cap on the dose, while others may experience severe neuropathy at the same dose. Contrary to previous genomics based approaches, we employed a metabolomics approach to identify small sets of metabolites that can be used to predict a patient’s susceptibility to peripheral neuropathy at different time points during the treatment. Using those identified metabolites, we developed a novel strategy to predict peripheral neuropathy and subsequently adjust the vincristine dose accordingly. In accordance with this novel strategy, we created a free user-friendly tool, VIPNp, for physicians to easily implement our prediction strategy. Our results showed that focusing on metabolites, which encompasses both genotypic and phenotypic variations, can enable early prediction of peripheral neuropathy in pediatric leukemia patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded, in part, with support from Grant Number R01HD062484-06 from the National Institutes of Health and National Institute of Child Health and Human Development, and Indiana Clinical and Translational Sciences Institute funded, in part by Grant Number UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur trained models are available on https://github.com/parulv1/VIPNp. The metabolite profiles are available from the corresponding author on reasonable request.